2024-03-29T14:33:43Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/113442023-10-11T11:29:44Zcom_20.500.12105_2174com_20.500.12105_2051com_20.500.12105_2173col_20.500.12105_2175
00925njm 22002777a 4500
dc
Cedena, Maria-Teresa
author
Martin-Clavero, Estela
author
Wong, Sandy
author
Shah, Nina
author
Bahri, Natasha
author
Alonso, Rafael
author
Barcenas, Carmen
author
Valeri, Antonio
author
Salazar Tabares, Johny
author
Sanchez-Pina, Jose
author
Cuellar, Clara
author
Martin, Thomas
author
Wolf, Jeffrey
author
Lahuerta, Juan José
author
Martinez-Lopez, Joaquin
author
2020-08-31
Stringent complete response (sCR) is used as a deeper response category than complete response (CR) in multiple myeloma (MM) but may be of limited value in the era of minimal residual disease (MRD) testing.
Here, we used 4-colour multiparametric flow cytometry (MFC) or next-generation sequencing (NGS) of immunoglobulin genes to analyse and compare the prognostic impact of sCR and MRD monitoring. We included 193 treated patients in two institutions achieving CR, for which both bone marrow aspirates and biopsies were available.
We found that neither the serum free light chain ratio, clonality by immunohistochemistry (IHC) nor plasma cell bone marrow infiltration identified CR patients at distinct risk. Patients with sCR had slightly longer progression-free survival. Nevertheless, persistent clonal bone marrow disease was detectable using MFC or NGS and was associated with significantly inferior outcomes compared with MRD-negative cases.
Our results confirm that sCR does not predict a different outcome and indicate that more sensitive techniques are able to identify patients with differing prognoses. We suggest that MRD categories should be implemented over sCR for the future classification of MM responses.
PLoS One 2020 ;15(8):e0237155.
http://hdl.handle.net/20.500.12105/11344
32866200
10.1371/journal.pone.0237155
PloS one
STEM-CELL TRANSPLANTATION
DEEP-SEQUENCING METHOD
CRITERIA
THERAPY
IMPACT
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.